Regencell Bioscience HoldingRGC
13F holders, Q1 2025 (March 31)5holders +2
3new positions
1sold out
$31.85avg. 13F price*
At the end of Q1 2025, 5 institutions reported holding Regencell Bioscience Holding (RGC) in their 13F filings, up 2 from Q4 2024. 3 opened new positions and 1 sold out. The largest holders were Geode Capital Management, LLC ($217K), Royal Bank of Canada ($30K) and Tower Research Capital LLC (TRC) ($22K).
- Company
- Regencell Bioscience Holding
- CUSIP
- G7487R100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $270K |
| Exits | 1 | $144K |
All 13F filers, Q4 2024 → Q1 2025: 8,587 shares bought and 31,313 shares sold, net −22,726 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Geode Capital Management, LLC | 0.00% | New | 6,816 | $217K |
| Royal Bank of Canada | 0.00% | New | 948 | $30K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 698 | $22K |
| BlackRock, Inc. | 0.00% | Add +52.5% | 363 | $12K |
| Morgan Stanley | 0.00% | Reduce -99.8% | 5 | $159 |
"% of holder's portfolio" is RGC's weight in each manager's 13F, not the share of Regencell Bioscience Holding the manager owns.